Tag: Kymera Therapeutics

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Kymera Therapeutics

With $65 Million in Hand, Kymera Will Put Its Protein Degradation Technology to the Test

Added to Collection on: 2018-11-12 22:26:15

Tags for this article:

Biology
Cell biology
Molecular biology
Proteins
Cambridge
Sanofi
Posttranslational modification
Proteasome
Ubiquitin ligase
Ubiquitin
Kymera Therapeutics

Click the tags to see associated articles and topics

View Article Details
Vertex follows pharma lead in bet on protein degradation

Added to Collection on: 2019-05-14 23:56:15

Tags for this article:

Spinal muscular atrophy
Antisense RNA
Life Sciences
Biotechnology
Health care
Huntington's disease
Ionis Pharmaceuticals
Atlas Venture
Biogen
Alnylam Pharmaceuticals
Nusinersen
Kymera Therapeutics

Click the tags to see associated articles and topics

View Article Details
Kymera Promotes Nello Mainolfi to President & CEO

Added to Collection on: 2019-11-22 08:00:00

Tags for this article:

Atlas Venture
Novartis
Xconomy
Pharmaceutical companies
Black Majesty
KRAS
Companies
Life Sciences
Frank Vinluan
Kymera Therapeutics

Click the tags to see associated articles and topics

View Article Details
Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at HC Wainwright

Added to Collection on: 2020-12-04 06:45:00

Tags for this article:

Economy
Occupations
Securities research
Stock market
Kymera Therapeutics
S&P 500 INDEX - CBOE

Click the tags to see associated articles and topics

View Article Details
Novel Rheumatoid Arthritis drugs succeed in the clinical trials: A status report by DelveInsight

Added to Collection on: 2021-03-19 01:30:00

Tags for this article:

Medical specialties
Clinical medicine
Health care
Rheumatology
Monoclonal antibodies
Arthritis
Immunosuppressants
TNF inhibitors
Rheumatoid arthritis
Sanofi
Bristol-Myers Squibb
Astellas Pharma
Baylx
Genor Biopharma
Novartis
Amgen
r-pharm
Kymera Therapeutics
TAISHO PHARMACEUTICAL
Arthrogen
Kang Stem Biotech
Sorrento Therapeutics
Gilead Sciences
Celltex Therapeutics
Bristol-Myers Squibb

Click the tags to see associated articles and topics

View Article Details
Kymera Therapeutics' $250.8M Offering: A Strategic Gamble on Protein Degradation?

Added to Collection on: 2025-06-27 07:50:14

Tags for this article:

Kymera
Kymera Therapeutics

Click the tags to see associated articles and topics

View Article Details
Book a Demo